Browsing Cancer Therapeutics by publication type "Thesis or Dissertation"

Now showing items 21-25 of 25

    • Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer 

      Sheehan, B (Institute of Cancer Research (University Of London), 2022-03-31)
      Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...

    • Targeting androgen receptor splicing in lethal prostate cancer 

      de Bono, J; Paschalis, A (Institute of Cancer Research (University Of London), 2021-04-30)
      Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...

    • Targeting therapeutic vulnerabilities associated with EWS fusion proteins in Ewing sarcoma 

      Shipley J; Romo Morales, A; Shipley, J (Institute of Cancer Research (University Of London), 2021-01-31)
      Ewing sarcoma (ES) is a are and aggressive bone tumour affecting children and young adults and that requires better therapeutic options to improve patient outcomes. ES is characterised by chromosomal rearrangements producing ...

    • The molecular pathology of infant gliomas 

      Jones, C; Clarke, M (Institute of Cancer Research (University Of London), 2021-04-30)
      Infant high grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumours. I have collected 241 cases ...

    • Unravelling the mechanisms of acquired immunomodulatory drug resistance in multiple myeloma 

      Pawlyn C; Bird, S; Pawlyn, C (Institute of Cancer Research (University Of London), 2023-12-01)
      Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma treatment and newer cereblon E3 ligase modulating drugs (CELMoDs) are in clinical trials. However, a major barrier to improving patient outcomes is ...